Codexis Strikes Major Deal with Crosswalk Therapeutics for Fabry and Pompe Disease Compounds

Codexis Inc., known for its enzyme engineering expertise, has signed an agreement to sell its investigational compounds for Fabry and Pompe diseases to Crosswalk Therapeutics.

As part of this deal, Codexis will be eligible for future payments based on development and commercial milestones, along with a royalty in the low-to-mid single-digit percentage range on net sales.

"We're excited to entrust these promising programs to the experienced team at Crosswalk Therapeutics. Since we announced our strategic shift last year, we've successfully monetized several non-core assets, allowing us to concentrate on our high-value initiatives. The leadership at Crosswalk, comprising former Takeda rare diseases team members familiar with these programs, makes them the perfect partner to further develop these therapies for the benefit of patients," said Kevin Norrett, MBA, Chief Operating Officer at Codexis.

These programs were initially part of a collaboration between Codexis and Takeda. However, Takeda discontinued its AAV gene therapy efforts, including these programs, in April 2023.